Versor Investments LP Raises Stock Holdings in Glaukos Corporation $GKOS

Versor Investments LP lifted its holdings in shares of Glaukos Corporation (NYSE:GKOS) by 143.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,272 shares of the medical instruments supplier’s stock after purchasing an additional 7,830 shares during the quarter. Versor Investments LP’s holdings in Glaukos were worth $1,306,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Primecap Management Co. CA grew its holdings in shares of Glaukos by 0.3% during the first quarter. Primecap Management Co. CA now owns 1,218,475 shares of the medical instruments supplier’s stock worth $119,922,000 after purchasing an additional 4,150 shares in the last quarter. Westfield Capital Management Co. LP boosted its stake in Glaukos by 34.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,084,184 shares of the medical instruments supplier’s stock worth $106,705,000 after buying an additional 277,033 shares in the last quarter. Gilder Gagnon Howe & Co. LLC boosted its stake in Glaukos by 25.3% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 825,276 shares of the medical instruments supplier’s stock worth $123,742,000 after buying an additional 166,677 shares in the last quarter. Northern Trust Corp boosted its stake in Glaukos by 7.4% in the fourth quarter. Northern Trust Corp now owns 578,673 shares of the medical instruments supplier’s stock worth $86,766,000 after buying an additional 40,052 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in Glaukos by 21.8% in the first quarter. Principal Financial Group Inc. now owns 327,036 shares of the medical instruments supplier’s stock worth $32,187,000 after buying an additional 58,502 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Stock Performance

Shares of GKOS stock opened at $89.92 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. Glaukos Corporation has a fifty-two week low of $77.10 and a fifty-two week high of $163.71. The stock has a 50 day moving average price of $96.84 and a two-hundred day moving average price of $102.97. The company has a market capitalization of $5.16 billion, a P/E ratio of -54.50 and a beta of 0.78.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.02. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%. The firm had revenue of $124.12 million during the quarter, compared to the consensus estimate of $115.49 million. During the same quarter in the previous year, the company posted ($0.52) earnings per share. The business’s revenue was up 29.7% on a year-over-year basis. Analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current year.

Analysts Set New Price Targets

GKOS has been the subject of several research reports. UBS Group upped their target price on Glaukos from $125.00 to $134.00 and gave the stock a “buy” rating in a research note on Thursday, July 31st. Stifel Nicolaus cut their target price on Glaukos from $140.00 to $115.00 and set a “buy” rating for the company in a research note on Thursday, May 1st. BTIG Research reaffirmed a “buy” rating on shares of Glaukos in a research note on Monday, July 14th. Wells Fargo & Company upped their target price on Glaukos from $86.00 to $92.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 31st. Finally, Needham & Company LLC cut their target price on Glaukos from $176.00 to $115.00 and set a “buy” rating for the company in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $127.42.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.